Sun Pharma declares five-year positive results for ILUMYA (tildrakizumab-asmn) EP News Bureau Nov 1, 2020 ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses
Sun Pharma presents insights into clinical use of ILUMYA in moderate-to-severe plaque psoriasis EP News Bureau Jun 13, 2020 Reportedly, updated cost analysis reveals ILUMYA is among the most cost-effective first-line treatments for moderate-to-severe…
